# People Using GLP-1s Like Ozempic and Wegovy Exercise Less, Study Finds
A new study reveals that people taking GLP-1 receptor agonist medications, including Ozempic and Wegovy, exercise significantly less than those not using these drugs. The research raises questions about long-term health outcomes for the millions of Americans now using these popular weight-loss and diabetes medications.
GLP-1 drugs work by reducing appetite and slowing stomach emptying, making people feel fuller longer. While this helps with weight loss, it appears to reduce the motivation to move. People on these medications reported lower physical activity levels across multiple studies, even as their weight declined.
This matters because exercise offers benefits that weight loss alone cannot. Physical activity strengthens the heart, improves bone density, boosts mental health, and reduces risk for numerous diseases. When people lose weight without exercising, they may lose muscle mass along with fat. This trade-off can slow metabolism and make long-term weight maintenance harder.
Doctors express concern about the pattern. As patients reach their weight loss goals on GLP-1s, many feel no urgency to start exercising. The medications feel like a complete solution. But the research suggests this approach leaves gaps in overall health.
The good news: healthcare providers can address this directly. Doctors prescribing GLP-1s should explicitly discuss exercise benefits and create concrete plans with patients. Starting with short walks or gentle strength training, then building from there, works better than waiting for motivation to appear.
Parents should also note that some adolescents now use these medications for weight loss. The same risks apply. Young people on GLP-1s benefit from intentional conversations about movement, not just medication compliance.
The takeaway for families: these medications are tools, not replacements for healthy habits. Weight loss plus exercise beats weight loss alone, every